CT38 peptide in the InTiME ME/CFS pilot
Pereira G et al. · 2021 · Frontiers in Systems Neuroscience
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Open-label subcutaneous infusion of the 40-amino-acid peptide as its acetate salt at 0.01, 0.03, 0.06 or 0.20 μg/kg/h, for up to 10.5 hours. The total daily symptom score combined 13 self-reported symptoms across the 28 days before and after treatment.
Dose, route and schedule
Open-label subcutaneous infusion of the 40-amino-acid peptide as its acetate salt at 0.01, 0.03, 0.06 or 0.20 μg/kg/h, for up to 10.5 hours. The total daily symptom score combined 13 self-reported symptoms across the 28 days before and after treatment.
Protocol source ↗ · Original source
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| 28-day symptom score in the lower-exposure subgroup | Among 10 participants with peak concentration below 0.25 ng/mL, the mean score went from 29.1 to 22.9 (−21.4%, p=0.003). The two participants assigned the highest infusion rate had higher symptom scores after treatment. | |
| Tolerability | Two participants stopped study drug early and completed follow-up. One had symptoms after infusion and one had difficulty with venous access. |
The study was exploratory and had no placebo arm. The concentration-based subgroup analysis used 10 participants. The sponsor owns rights to the peptide and took part in analysis.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The study was exploratory and had no placebo arm. The concentration-based subgroup analysis used 10 participants. The sponsor owns rights to the peptide and took part in analysis.
Related publications may cover the same research program or participants.
Source access
Open-label subcutaneous infusion of the 40-amino-acid peptide as its acetate salt at 0.01, 0.03, 0.06 or 0.20 μg/kg/h, for up to 10.5 hours. The total daily symptom score combined 13 self-reported symptoms across the 28 days before and after treatment.
Source reviewed 2026-11-12.
Citation and original source
Original source: Pereira G et al.. CT38 peptide in the InTiME ME/CFS pilot Frontiers in Systems Neuroscience 2021.
Molekul research summary: https://molekul.io/research/ct38-intime-2021. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry